All In Biotech

Drug Trial Radar · NCT07910097

Flurpiridaz F-18 PET/CT Imaging for Detecting Parathyroid Adenomas

Flurpiridaz F-18 PET/CT Imaging for Detecting Parathyroid Adenomas in Patients With Primary Hyperparathyroidism

Last checked: Nov 20, 2026Latest source record: Nov 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

20

Planned (sponsor's estimate)

Start

Aug 15, 2026

Primary completion

Sep 1, 2028

Study completion Sep 1, 2029

Sponsor

Lead sponsor
University of PennsylvaniaAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Nov 2, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Early phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Diagnostic
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Study of Flurpiridaz F-18 positron emission tomography/computed tomography (PET/CT) as a diagnostic imaging tool to detect abnormal parathyroid glands in patients with primary hyperparathyroidism, prior to multi-parathyroid gland surgical exploration. Patients with known or suspected parathyroid adenomas will be eligible for this study. Comparisons of diagnostic performance using Flurpiridaz F-18 PET/CT versus standard of care dual time point sestamibi single photon emission computed computed tomography/computed tomography (SPECT/CT) imaging will be tested.

Conditions

  • Hyperparathyroidism

Interventions

  • Flurpiridaz PET/CTDrug

    Flurpiridaz is a FDA approved radiopharmaceutical used with PET/CT imaging

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. SensitivityTime frame: 4 weeks
  2. sensitivityTime frame: 6 weeks

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Unversity of Pennsylvania

    Philadelphia, Pennsylvania · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.